Q1 2026 · 13F-HR
Birchview Capital, LPholdings as filed
Filed 2026-05-15 · accession 0001618205-26-000002
$175.7M
Reported value
73
Positions
2026-03-31
Period end
The Brief · Birchview Capital, LP · Q1 2026
AI · grounded in 13F
Birchview Capital, LP closed its position in Amicus Therapeutics Inc AM6, reducing exposure by $3.6M. The fund established new positions in Relmada Therapeutics Inc RLMD for $2.8M and Ocular Therapeutix Inc OCUL for $2.7M. Additionally, the fund increased its stake in Intellia Therapeutics Inc NTLA by 41.2%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 482480100 | KLAC | KLA CORPORATION | $29.3M | 16.7% | 19,883 | Common | SOLE |
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $18.6M | 10.6% | 306,268 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $7.8M | 4.41% | 1,465,867 | Common | SOLE |
| 512807306 | LRCX | LAM RESEARCH CORPORATION | $7.7M | 4.38% | 36,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $6.8M | 3.89% | 210,000 | Common | SOLE |
| 69047Q102 | OVV | OVINTIV INC | $6.4M | 3.63% | 107,500 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $5.7M | 3.25% | 445,400 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $4.8M | 2.74% | 100,000 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $4.5M | 2.57% | 625,980 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $4.4M | 2.48% | 449,019 | Common | SOLE |
| 09075X108 | BDSX | BIODESIX INC | $4.2M | 2.37% | 286,804 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $3.8M | 2.17% | 171,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $3.7M | 2.10% | 35,000 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $3.6M | 2.04% | 27,190 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $3.3M | 1.86% | 219,000 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $2.8M | 1.62% | 409,387 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $2.7M | 1.54% | 320,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $2.7M | 1.52% | 4,500 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $2.2M | 1.27% | 31,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC | $2.2M | 1.27% | 70,095 | Common | SOLE |
| G6674U108 | NVCR | NOVOCURE LTD | $2.2M | 1.26% | 202,330 | Common | SOLE |
| 26884L109 | EQT | EQT CORPORATION | $2.2M | 1.25% | 34,619 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $2.2M | 1.23% | 195,000 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $2.2M | 1.22% | 463,599 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS LTD | $2.1M | 1.18% | 375,000 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA INC | $2.0M | 1.13% | 1,500,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $2.0M | 1.13% | 30,000 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $1.9M | 1.08% | 47,200 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $1.8M | 1.01% | 44,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $1.8M | 1.01% | 50,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $1.7M | 0.97% | 250,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $1.6M | 0.94% | 100,697 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $1.4M | 0.78% | 70,000 | Common | SOLE |
| 74838J101 | QDELUSD | QUIDELORTHO CORP | $1.4M | 0.77% | 82,548 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $1.3M | 0.77% | 281,730 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $1.3M | 0.74% | 62,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $1.2M | 0.70% | 21,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $1.1M | 0.65% | 57,000 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $1.1M | 0.62% | 50,000 | Common | SOLE |
| 35671D857 | FCX | FREEPORT-MCMORAN CL-B | $1.1M | 0.60% | 18,040 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $1.0M | 0.58% | 6,000 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $916,650 | 0.52% | 5,000 | Common | SOLE |
| 53630X203 | LPCN | LIPOCINE INC | $893,170 | 0.51% | 111,786 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $867,532 | 0.49% | 29,200 | Common | SOLE |
| 415858109 | HROW | HARROW HEALTH INC | $846,240 | 0.48% | 24,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $843,178 | 0.48% | 29,847 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $795,000 | 0.45% | 150,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $757,530 | 0.43% | 9,000 | Common | SOLE |
| 40637H109 | HALO | HALOZYME THERAPEUTICS INC | $652,763 | 0.37% | 10,100 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $645,171 | 0.37% | 8,688 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $563,220 | 0.32% | 14,000 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $561,775 | 0.32% | 16,860 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $559,202 | 0.32% | 25,889 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $555,343 | 0.32% | 66,270 | Common | SOLE |
| 48576U106 | KPTIEUR | KARYOPHARM THERAPEUTICS INC | $467,613 | 0.27% | 83,952 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $454,750 | 0.26% | 127,025 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $393,156 | 0.22% | 20,100 | Common | SOLE |
| 690145107 | OMGBP | OUTSET MEDICAL INC | $379,707 | 0.22% | 98,882 | Common | SOLE |
| 745848101 | LUNG | PULMONX CORP | $322,785 | 0.18% | 250,221 | Common | SOLE |
| 14843C105 | CSTL | CASTLE BIOSCIENCES INC | $316,695 | 0.18% | 12,900 | Common | SOLE |
| 896442308 | TRIN | TRINITY CAP INC | $294,200 | 0.17% | 20,000 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $294,000 | 0.17% | 60,000 | Common | SOLE |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $289,183 | 0.16% | 74,918 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $284,200 | 0.16% | 20,000 | Common | SOLE |
| 48662X105 | KBDC | KAYNE ANDERSON BDC INC | $274,400 | 0.16% | 20,000 | Common | SOLE |
| 00439U104 | GRCE | GRACE THERAPEUTICS INC | $231,500 | 0.13% | 50,000 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $173,349 | 0.10% | 165,094 | Common | SOLE |
| 31572Q881 | KYNB | KYNTRA BIO INC | $152,997 | 0.09% | 22,566 | Common | SOLE |
| 74907L409 | QNRX | QUOIN PHARMACEUTICALS LTD | $132,000 | 0.08% | 20,000 | Common | SOLE |
| 71944F106 | PHR | PHREESIA INC | $119,834 | 0.07% | 14,300 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $40,957 | 0.02% | 17,503 | Common | SOLE |
| 256086109 | DCGO | DOCGO INC | $24,895 | 0.01% | 39,573 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $5,971 | 0.00% | 18,176 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.